In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...

Oric Pharmaceuticals (ORIC) announced focused registrational clinical development plans for its two lead programs, an extension of projected ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic castration-resistant prostate cancer. Real-world evidence suggests that ...

Darolutamide demonstrated longer treatment duration and delayed progression to metastatic CRPC compared to enzalutamide and apalutamide in Black and White patients. The DEAR and DEAR-EXT studies ...

Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China Background: Skin adverse events of apalutamide pose a major ...

Huntsman Cancer Center is another renowned center to be added to support the Company’s randomized trial for patients receiving either apalutamide or apalutamide+ENV105 combination therapy.

To review the efficacy and safety of low-dose versus standard-dose enzalutamide, apalutamide or darolutamide treatment for metastatic prostate cancer. Keyword searches in MEDLINE and EMBASE up to 1 ...

Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase ...